BR112015031724A2 - use of nl-1 serlopitant receptor antagonist in pruritus - Google Patents

use of nl-1 serlopitant receptor antagonist in pruritus

Info

Publication number
BR112015031724A2
BR112015031724A2 BR112015031724A BR112015031724A BR112015031724A2 BR 112015031724 A2 BR112015031724 A2 BR 112015031724A2 BR 112015031724 A BR112015031724 A BR 112015031724A BR 112015031724 A BR112015031724 A BR 112015031724A BR 112015031724 A2 BR112015031724 A2 BR 112015031724A2
Authority
BR
Brazil
Prior art keywords
serlopitant
pruritus
receptor antagonist
receptor antagonists
additional
Prior art date
Application number
BR112015031724A
Other languages
Portuguese (pt)
Inventor
J Perlman Andrew
F Schnipper Edward
W Larrick James
Zhang Xiaoming
Original Assignee
Tigercat Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/925,509 external-priority patent/US8906951B1/en
Application filed by Tigercat Pharma Inc filed Critical Tigercat Pharma Inc
Publication of BR112015031724A2 publication Critical patent/BR112015031724A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

1/1 resumo “uso do antagonista do receptor nk-1 serlopitant em pruridos” a invenção refere-se a métodos para o tratamento de prurido com antagonistas do receptor nk-1 tais como serlopitant. a invenção refere-se ainda a composições farmacêuticas compreendendo antagonistas do receptor nk-1, tais como serlopitant. além disso, a invenção abrange o tratamento de uma condição associada com prurido com serlopitant e um agente antipruriginoso adicional, e o uso de serlopitant como um auxiliar de sono, opcionalmente em combinação com um agente de ajuda de sono adicional.1/1 abstract "use of nk-1 receptor antagonist serlopitant in pruritus" The invention relates to methods for treating pruritus with nk-1 receptor antagonists such as serlopitant. the invention further relates to pharmaceutical compositions comprising nk-1 receptor antagonists, such as serlopitant. further, the invention encompasses treating a condition associated with pruritus with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep aiding agent.

BR112015031724A 2013-06-24 2014-06-24 use of nl-1 serlopitant receptor antagonist in pruritus BR112015031724A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361838784P 2013-06-24 2013-06-24
US13/925,509 US8906951B1 (en) 2013-06-24 2013-06-24 Use of NK-1 receptor antagonists in pruritus
PCT/US2014/043811 WO2014209962A1 (en) 2013-06-24 2014-06-24 Use of nk-1 receptor antagonist serlopitant in pruritus

Publications (1)

Publication Number Publication Date
BR112015031724A2 true BR112015031724A2 (en) 2017-07-25

Family

ID=51230173

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015031724A BR112015031724A2 (en) 2013-06-24 2014-06-24 use of nl-1 serlopitant receptor antagonist in pruritus

Country Status (13)

Country Link
EP (1) EP3013336A1 (en)
JP (2) JP2016523260A (en)
KR (1) KR20160023692A (en)
CN (1) CN105473138A (en)
AU (2) AU2014302694B2 (en)
BR (1) BR112015031724A2 (en)
CA (1) CA2915474A1 (en)
HK (1) HK1223820A1 (en)
IL (1) IL243189A0 (en)
MX (2) MX366728B (en)
PH (2) PH12015502777A1 (en)
RU (1) RU2666219C2 (en)
WO (1) WO2014209962A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9808465B2 (en) 2014-09-19 2017-11-07 Heron Therapeutics, Inc. Emulsion formulations of aprepitant
JP6891385B2 (en) 2015-03-04 2021-06-18 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Treatment with Tradipitant
EP3411013A1 (en) * 2016-02-01 2018-12-12 Heron Therapeutics, Inc. Emulsion comprising an nk-1 receptor antagonist
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
CA3029478A1 (en) * 2016-06-29 2018-01-04 Menlo Therapeutics Inc. Use of neurokinin-1 antagonists to treat a variety of pruritic conditions
CN111093671A (en) * 2017-09-13 2020-05-01 万达制药公司 Improved treatment of atopic dermatitis with tropiptan
BR112020008714A2 (en) * 2017-11-01 2020-11-03 National University Of Singapore use of serotonergic drugs to treat virus-induced thrombocytopenia
EP3746086A4 (en) * 2018-01-31 2021-10-20 TWI Biotechnology, Inc. Topical formulations comprising tofacitinib
CN117503699A (en) * 2023-12-08 2024-02-06 斯坦德医药研发(江苏)有限公司 Aprepitant oral liquid preparation and preparation method thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100565A1 (en) 2001-09-21 2003-05-29 Boehringer Ingelheim International Gmbh Method for the treatment or prevention of atopic dermatitis
CN100582093C (en) * 2004-01-27 2010-01-20 默克公司 Hydroisoindoline tachykinin receptor antagonists
TWI341198B (en) 2004-01-27 2011-05-01 Merck Sharp & Dohme Hydroisoindoline tachykinin receptor antagonists
US20100036135A1 (en) 2005-07-11 2010-02-11 Merck & Co., Inc. Process for Making Hydroisoindoline Tachykinin Receptor Antagonists
AU2006302562A1 (en) 2005-10-04 2007-04-19 Merck Sharp & Dohme Corp. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2007146224A2 (en) 2006-06-12 2007-12-21 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
EP2063885A2 (en) * 2006-09-06 2009-06-03 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
WO2008054690A2 (en) 2006-11-02 2008-05-08 Merck & Co., Inc. Polymorphs of a hydroisoindoline tachykinin receptor antagonist
US20100113469A1 (en) 2007-03-29 2010-05-06 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
RU2370265C1 (en) * 2008-03-04 2009-10-20 Лев Давидович Раснецов Gel, possessing anti- inflammatory and antiallergic effect

Also Published As

Publication number Publication date
MX366728B (en) 2019-07-22
RU2015154037A (en) 2017-07-28
MX2015017763A (en) 2016-06-21
HK1223820A1 (en) 2017-08-11
RU2666219C2 (en) 2018-09-06
AU2014302694B2 (en) 2019-10-17
CA2915474A1 (en) 2014-12-31
MX2019008643A (en) 2019-09-10
PH12020500255A1 (en) 2021-02-22
KR20160023692A (en) 2016-03-03
CN105473138A (en) 2016-04-06
PH12015502777A1 (en) 2016-03-21
EP3013336A1 (en) 2016-05-04
AU2014302694A1 (en) 2016-01-07
WO2014209962A1 (en) 2014-12-31
JP2016523260A (en) 2016-08-08
IL243189A0 (en) 2016-02-29
AU2020200259A1 (en) 2020-02-06
JP2019142960A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
BR112015031724A2 (en) use of nl-1 serlopitant receptor antagonist in pruritus
PH12016500642A1 (en) Selective substituted quinoline compounds
TR201902516T4 (en) Glucagon-glp-1-envy triple agonist compounds.
UA113440C2 (en) TETRAHYDROPYRAZYLOPYRIMIDINE COMPOUNDS
JOP20140141B1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
SA516370641B1 (en) Heterocyclic compounds and methods of use
ECSP16008797A (en) DERIVATIVES OF HETEROBICICLOARIL AS RORC2 INHIBITORS AND METHODS OF USE OF THE SAME
PH12015501627A1 (en) Kv1.3 antagonists and methods of use
MX2016006975A (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases.
CL2016000325A1 (en) Track antagonists to treat sleep disorders due to phase change
PH12020550185A1 (en) Semaglutide in medical therapy
CL2016001570A1 (en) Use of an opioid receptor antagonist with% u039a and vortioxetine activity for the treatment of depressive disorder with melancholic characteristics
BR112017013208A2 (en) octenidine use
BR112015032668A8 (en) fluid and sparkling composition of personal care and method for preparing a composition
CL2012003253A1 (en) Compounds derived from 1,3,4-thiadiazole alkylamides and chalconas, trpv-1 receptor antagonists; use of compounds to treat chronic pain.
PH12017501214A1 (en) Cgrp antagonist peptides
CR20140489A (en) USE OF 18-METIL-15B, 16B-METILEN-19-NOR-20-ESPIROX-4-EN-3-ONAS IN THE TREATMENT OF MENORRAGY, AND INTRAUTERINE SYSTEMS THAT INCLUDE 18-METIL-15B, 16B-METILEN-19- NOR-20-ESPIROX-4-EN-3-ONAS FOR THE TREATMENT OF T
PL413540A1 (en) Composition for integration of sands
ME03086B (en) Kv1.3 antagonists and methods of use

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MENLO THERAPEUTICS INC. (US)

B25G Requested change of headquarter approved

Owner name: MENLO THERAPEUTICS INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]